In last trading session, Compass Therapeutics Inc (NASDAQ:CMPX) saw 0.3 million shares changing hands with its beta currently measuring 0.72. Company’s recent per share price level of $1.88 trading at $0.07 or 3.87% at ring of the bell on the day assigns it a market valuation of $258.67M. That closing price of CMPX’s stock is at a discount of -24.47% from its 52-week high price of $2.34 and is indicating a premium of 59.57% from its 52-week low price of $0.76. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.49 million shares which gives us an average trading volume of 447.84K if we extend that period to 3-months.

For Compass Therapeutics Inc (CMPX), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.14. Splitting up the data highlights that, out of 2 analysts covering the stock, 1 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 1 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.11 in the current quarter.

Compass Therapeutics Inc (NASDAQ:CMPX) trade information

Upright in the green during last session for gaining 3.87%, in the last five days CMPX remained trading in the green while hitting it’s week-highest on Friday, 09/27/24 when the stock touched $1.88 price level, adding 2.59% to its value on the day. Compass Therapeutics Inc’s shares saw a change of 20.51% in year-to-date performance and have moved 13.25% in past 5-day. Compass Therapeutics Inc (NASDAQ:CMPX) showed a performance of 57.98% in past 30-days. Number of shares sold short was 2.3 million shares which calculate 6.05 days to cover the short interests.

Wall Street analysts have assigned a consensus price target of 5 to the stock, which implies a rise of 62.4% to its current value. Analysts have been projecting 5 as a low price target for the stock while placing it at a high target of 5. It follows that stock’s current price would drop -165.96% in reaching the projected high whereas dropping to the targeted low would mean a loss of -165.96% for stock’s current value.

Compass Therapeutics Inc (CMPX) estimates and forecasts

Statistics highlight that Compass Therapeutics Inc is scoring comparatively lower than the scores of other players of the relevant industry. The company lost -5.05% of value to its shares in past 6 months, showing an annual growth rate of -27.27% while that of industry is 17.70. Apart from that, the company came lowering its revenue forecast for fiscal year 2024.

Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 12.88% during past 5 years.

Compass Therapeutics Inc (NASDAQ:CMPX)’s Major holders

Insiders are in possession of 12.04% of company’s total shares while institution are holding 72.08 percent of that, with stock having share float percentage of 81.95%. Investors also watch the number of corporate investors in a company very closely, which is 72.08% institutions for Compass Therapeutics Inc that are currently holding shares of the company. ORBIMED ADVISORS LLC is the top institutional holder at CMPX for having 22.36 million shares of worth $22.36 million. And as of 2024-06-30, it was holding 16.3701 of the company’s outstanding shares.

The second largest institutional holder is ADAGE CAPITAL PARTNERS GP, L.L.C., which was holding about 11.13 million shares on 2024-06-30. The number of shares represents firm’s hold over 8.1474 of outstanding shares, having a total worth of $11.13 million.